Cause Behind Biotech Stocks’ Unusual Volume- Repligen Corporation (NASDAQ:RGEN), Zalicus Inc (NASDAQ:ZLCS), Idera Pharmaceuticals Inc (NASDAQ:IDRA)
Repligen Corporation (RGEN) replaced Hi-Tech Pharmacal Co., Inc. (HITK) in the S&P SmallCap 600 following the close of trading on Thursday, April 17. S&P SmallCap 600 ingredient Akorn Inc. (AKRX) is purchasing Hi-Tech Pharmacal Co. in an agreement anticipated to be completed soon. Repligen Corporation is a life sciences firm focused on the development, production, and commercialization of high-value consumable products used in the process of manufacturing biological drugs.
Repligen Corporation (NASDAQ:RGEN) [Trend Analysis] after opening at $15.30 hit its intraday high price of $16.22 moreover then finished at $15.48 by shares raised 2.86%. At Wall Street for latest quarter, the consensus average estimates of street for the revenue are $15.30M, at the same time as one experts forecast $14.60M revenues for the next three months of 2014.
Gets Free Inside Facts on (NASDAQ:RGEN)
Zalicus Inc. (NASDAQ:ZLCS) aims to release its first quarter results on Apr 28, 2014. The is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus Inc. (ZLCS) and Epirus Biopharmaceuticals, Inc., reported that they have signed into a definitive contract under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.
Zalicus Inc (NASDAQ:ZLCS) [Trend Analysis] shares trading performance in last session was noticeable, stocks slumped -10.37% with market capitalization of $31.57M, as outstanding shares was $26.09M. The recommendation trends from street professionals are, stock rated at “buy” by no analyst, while no analyst rates as a “sell” security.
Acts and Reacts in Analytic Report, Finds (NASDAQ:ZLCS)
Idera Pharmaceuticals, Inc. (IDRA) recently released that the new preclinical data demonstrating the aptitude of its Toll-like receptor (TLR) antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) [Trend Analysis] reported the fall of -5.78% and closed at $2.77 with the total traded volume of $3.02M shares. Its market capitalization was $228.14M. The stock owned by the Financial Institutions was 30%. The company’s shares have dropped -54.28% in last 30 days and -36.32% in previous three months, compared to a decrease of -4.30% and -2.43% in the Nasdaq during the respective periods.
What are Prospects of IDRA, Find the Free Technical Analysis
Read Full Disclaimer Here